4SC-202 |
| Catalog No.GC12667 |
4SC-202 (4SC-202) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. It also displays inhibitory activity against Lysine specific demethylase 1 (LSD1).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1186222-89-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
4SC-202 is a selective, potent and orally available inhibitor of histone deacetylases (HDAC) specific for class I HDAC isoenzymes with an IC50 value of about 1μM [1].
4SC-202 has been reported to selectively inhibit the recombinant class I HDAC isoenzymes with IC50 values of 1.2μM, 1.12μM and 0.57μM for HDAC-1, HDAC-2 and HDAC-3, respectively. In vitro studies, 4SC-202 has been revealed to induce hyperacetylation of histone H3 in a concentration-dependent fashion with an EC50 values of 1.1μM in HeLa and RKO cell lines. In addition, 4SC-202 has been demonstrated to induce a G2/M cell cycle arrest and enhance in sub G1 cells. In other words, 4SC-202 can induce the apoptotic in NSCLS cell lines. 4SC-202 has been noted to suppress proliferative activity in human cancer cell lines with a mean IC50 of 0.7μM.
In vivo studies, 4SC-202 has shown a good tolerability and dose-dependent effect on anti-tumour activity compared with other inhibitors in the A549NSCLC xenograft model and the RKO27 colon carcinoma model [1].
References:
[1] Henning S W, Doblhofer R, Kohlhof H, et al. 178 Preclinical characterization of 4SC-202, a novel isotype specific HDAC inhibitor[J]. European Journal of Cancer Supplements, 2010, 8(7): 61.
Average Rating: 5 (Based on Reviews and 11 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *